BG105567A - Експресионна система за фактор viii - Google Patents

Експресионна система за фактор viii

Info

Publication number
BG105567A
BG105567A BG105567A BG10556701A BG105567A BG 105567 A BG105567 A BG 105567A BG 105567 A BG105567 A BG 105567A BG 10556701 A BG10556701 A BG 10556701A BG 105567 A BG105567 A BG 105567A
Authority
BG
Bulgaria
Prior art keywords
factor viii
protein
cells
process includes
procoagulant activity
Prior art date
Application number
BG105567A
Other languages
English (en)
Other versions
BG65431B1 (bg
Inventor
Myung - Sam CHO
Sham - Yuen CHAN
William Kelsey
Helena Yee
Original Assignee
Bayer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corporation filed Critical Bayer Corporation
Publication of BG105567A publication Critical patent/BG105567A/bg
Publication of BG65431B1 publication Critical patent/BG65431B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Изобретението се отнася до метод за свободна от протеин продукция на белтъци, проявяващи прокоагулантна активност на фактор VIII. Най-общо методът включва получаване на стабилни човешки клетъчни клонове с висока продуктивност на фактор VIII с отстранен В домен и адаптиране на клетки за растеж в среда, свободна от плазмени белтъци. По-специално методът включва трансфектиране на човешки клетки с вектор, показан на фигурата, включващ селективен маркер и секвенция, кодираща белтъка, проявяващ прокоагулантна активност на фактор VIII, подбор на клетки със селективен агент и изолиране на клонове, експресиращи високи нива на посочения белтък.
BG105567A 1998-12-10 2001-06-06 Експресионна система за фактор viii BG65431B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII

Publications (2)

Publication Number Publication Date
BG105567A true BG105567A (bg) 2002-03-29
BG65431B1 BG65431B1 (bg) 2008-07-31

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105567A BG65431B1 (bg) 1998-12-10 2001-06-06 Експресионна система за фактор viii

Country Status (26)

Country Link
US (10) US6358703B1 (bg)
EP (1) EP1137797B1 (bg)
JP (1) JP4240818B2 (bg)
KR (1) KR100616028B1 (bg)
AT (1) ATE412765T1 (bg)
AU (1) AU761801B2 (bg)
BG (1) BG65431B1 (bg)
BR (1) BRPI9916069B8 (bg)
CA (1) CA2354845C (bg)
CZ (1) CZ302330B6 (bg)
DE (1) DE69939839D1 (bg)
DK (1) DK1137797T3 (bg)
ES (1) ES2315026T3 (bg)
HU (1) HU228489B1 (bg)
IL (2) IL143353A0 (bg)
NO (1) NO329544B1 (bg)
NZ (1) NZ512234A (bg)
PL (1) PL200676B1 (bg)
PT (1) PT1137797E (bg)
RO (1) RO121604B1 (bg)
RU (1) RU2249041C2 (bg)
SI (1) SI20644B (bg)
SK (1) SK286945B6 (bg)
TR (1) TR200101592T2 (bg)
UA (1) UA77383C2 (bg)
WO (1) WO2000034505A1 (bg)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
DK1266006T3 (da) * 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
AU2002310438B2 (en) 2001-06-14 2008-05-01 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
EP1636360A4 (en) * 2003-06-03 2006-11-08 Cell Genesys Inc COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
AU2005302516A1 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
HUE033776T2 (en) * 2004-11-12 2018-01-29 Bayer Healthcare Llc FVIII site-specific modification
KR101391457B1 (ko) 2005-12-20 2014-05-19 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
KR101818411B1 (ko) 2007-12-27 2018-01-12 박스알타 인코퍼레이티드 세포 배양 방법
KR101005967B1 (ko) 2008-04-12 2011-01-05 (주)셀트리온 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
EP2304046A4 (en) * 2008-06-25 2011-11-23 Bayer Healthcare Llc FACTOR VIII MUTES WITH REDUCED IMMUNOGENITY
BRPI0917656A2 (pt) 2008-08-21 2017-07-11 Octapharma Ag Fatores viii e ix humanos produzidos de forma recombinante
CN107050437A (zh) * 2008-09-03 2017-08-18 奥克塔法马股份有限公司 重组制备的因子viii的新型保护组合物
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2010111414A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
US9115381B2 (en) * 2011-05-13 2015-08-25 Octapharma Ag Method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII
BR112014017165B1 (pt) 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
ES2771208T3 (es) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
MY197302A (en) 2016-04-15 2023-06-12 Takeda Pharmaceuticals Co Method and apparatus for providing a pharmacokinetic drug dosing regimen
CN109475639A (zh) 2016-07-22 2019-03-15 尼克塔治疗公司 具有含肟键联的因子viii部分的轭合物
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
NZ769677A (en) 2018-05-18 2024-07-05 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CA3115535A1 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
ATE63335T1 (de) * 1986-07-11 1991-05-15 Miles Inc Herstellung von rekombinantem protein.
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
DE69433925T2 (de) * 1993-06-10 2005-07-28 Bayer Corp. Vektoren und Zelllinien von Säugetieren mit erhöhter Produktivität
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6180108B1 (en) 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression

Also Published As

Publication number Publication date
PT1137797E (pt) 2008-12-26
CZ20012024A3 (cs) 2001-10-17
US20160115219A1 (en) 2016-04-28
SI20644A (sl) 2002-02-28
NO20012718D0 (no) 2001-06-01
US8207117B2 (en) 2012-06-26
WO2000034505A1 (en) 2000-06-15
ATE412765T1 (de) 2008-11-15
UA77383C2 (uk) 2006-12-15
US9249209B2 (en) 2016-02-02
HUP0200558A3 (en) 2004-11-29
SK7922001A3 (en) 2002-01-07
US7459525B2 (en) 2008-12-02
PL349284A1 (en) 2002-07-15
TR200101592T2 (tr) 2001-11-21
JP4240818B2 (ja) 2009-03-18
US8945869B2 (en) 2015-02-03
IL143353A0 (en) 2002-04-21
EP1137797A4 (en) 2005-06-22
AU761801B2 (en) 2003-06-12
US20030077752A1 (en) 2003-04-24
HU228489B1 (en) 2013-03-28
US6358703B1 (en) 2002-03-19
RU2249041C2 (ru) 2005-03-27
US20130143818A1 (en) 2013-06-06
SK286945B6 (sk) 2009-08-06
KR20020013481A (ko) 2002-02-20
PL200676B1 (pl) 2009-01-30
IL143353A (en) 2010-12-30
EP1137797B1 (en) 2008-10-29
ES2315026T3 (es) 2009-03-16
BRPI9916069B8 (pt) 2021-05-25
NO329544B1 (no) 2010-11-08
BRPI9916069B1 (pt) 2016-08-02
DE69939839D1 (de) 2008-12-11
CA2354845A1 (en) 2000-06-15
DK1137797T3 (da) 2009-02-23
RO121604B1 (ro) 2007-12-28
BG65431B1 (bg) 2008-07-31
SI20644B (sl) 2009-04-30
CA2354845C (en) 2008-08-12
US20130267468A1 (en) 2013-10-10
EP1137797A1 (en) 2001-10-04
JP2002531137A (ja) 2002-09-24
BR9916069A (pt) 2001-09-04
US20090036358A1 (en) 2009-02-05
KR100616028B1 (ko) 2006-08-28
CZ302330B6 (cs) 2011-03-16
US20110144025A1 (en) 2011-06-16
US20170267745A1 (en) 2017-09-21
HUP0200558A2 (en) 2002-06-28
US20020115152A1 (en) 2002-08-22
NZ512234A (en) 2002-12-20
NO20012718L (no) 2001-06-01
US20020102730A1 (en) 2002-08-01
US9650431B2 (en) 2017-05-16
AU2170100A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
BG105567A (bg) Експресионна система за фактор viii
AU2795292A (en) Synthetic dna sequence having enhanced insecticidal activity in maize
AU1750297A (en) Humanized green fluorescent protein genes and methods
US6114148C1 (en) High level expression of proteins
ES8800359A1 (es) Metodo de produccion de factor viii:c humano
IE820069L (en) Recombinant dna encoding a polypeptide
US5786464C1 (en) Overexpression of mammalian and viral proteins
YU71002A (sh) Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama
AU3752795A (en) Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
IE881755L (en) Novel proteins with factor viii activity, process for their¹preparation using genetically engineered cells and¹pharmaceutical compositions containing them
WO1994011503A3 (en) Chimeric factor viii
EP0799317B8 (en) Method for secreting thrombopoietin polypeptides
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
EP0088195A3 (en) Messenger rna, production and use thereof
HK1002963A1 (en) A novel growth factor and a genetic sequence encoding same
DK1200561T3 (da) Rekombinant stabil celleklon, dens fremstilling og anvendelse
GR3033600T3 (en) Transformed endothelial cells.
DE3479816D1 (en) A promotor and use thereof
ES8700051A1 (es) Un procedimiento para preparar una composicion oral estable,formadora de espuma
GR3020790T3 (en) Achromobacter protease I gene and gene product thereof
ES8800353A1 (es) Procedimiento de clonacion de factor humano viii-r.
WO1998027200A3 (en) Human and mammalian dna replication origin consensus sequences
ATE266094T1 (de) Produktion des proteins ingap mit hoher expressionsrate
WO1994016074A3 (en) High molecular weight b-cell growth factor: interleukin-14
NZ332555A (en) Gene expression in monocytes and macrophages associated with the CD68 gene